
Information contained within this Announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 which forms part of English law by virtue of the
("Fiinu", the "Company" or the "Group")
The Loan carries an interest rate of 10% per annum, payable annually in cash, with a repayment date falling 24 months from drawdown, unless converted into Fiinu equity earlier in accordance with the terms of the Facility Agreement.
Under the Facility Agreement, Conister has the right to convert the entire Loan into 20 million new ordinary shares in Fiinu. This conversion price, of 10p per new ordinary share, was negotiated some time ago when Fiinu's share price was below 10p, and therefore reflects market conditions at that time. With Fiinu's shares currently trading at a premium to the agreed conversion price, the arrangement underscores both the financial flexibility of the facility and the strategic importance of the partnership between
Any shares issued pursuant to the conversion of the Loan will rank pari passu with the Company's existing ordinary shares and will be admitted to trading on AIM. The proceeds from the Loan will be used to support the Company's working capital requirements and to drive growth in Fiinu's businesses.
Commenting on the Agreement
Dr
"We are pleased to have secured this flexible financing arrangement with Conister, which not only strengthens our capital position but also provides us with additional working capital support for our fast-growing FX brokerage in
"This facility is part of the Group's strategy to enhance its lending technology by integrating with experienced market-leading product providers. The optionality within this facility also allows the Group to generate a return greater than debt interest alone, while positioning Manx Financial Group as a strategic partner with Fiinu."
Further announcements will be made as appropriate.
The Directors of the Company are responsible for the release of this announcement
*ENDS*
For further information, please contact:
Dr. |
Tel: +44 (0) 1932 629 532 |
|
|
|
Tel: +44 (0) 203 368 3550 |
|
|
|
Tel: +44 (0) 207 47 0470 |
|
|
|
Tel: +44 (0)203 179 5300 |
|
|
|
Tel: +44 (0) 207 785 7383 |
For more information, please visit www.fiinuplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the